Skip to main content
. Author manuscript; available in PMC: 2020 Jan 29.
Published in final edited form as: Methods Mol Biol. 2012;899:1–26. doi: 10.1007/978-1-61779-921-1_1

Table 2.

Therapeutic monoclonal antibodies approved or in review in the European Union or the USA

Name Trade name Type Indication first approved First EU (US) approval year
Muromonab-CD3 Orthoclone Okt3 Anti-CD3; Murine IgG2a Reversal of kidney transplant rejection 1986a(1986#2010@)
Abciximab Reopro Anti-GPIIb/IIIa; Chimeric IgG1 Fab Prevention of blood clots in angioplasty 1995a (1994)
Rituximab MabThera, Rituxan Anti-CD20; Chimeric IgG1 Non-Hodgkin’s lymphoma 1998 (1997)
Basiliximab Simulect Anti-IL2R; Chimeric IgG1 Prevention of kidney transplant rejection 1998 (1998)
Daclizumab Zenapax Anti-IL2R; Humanized IgG1 Prevention of kidney transplant rejection 1999 (1997); #2009
Palivizumab Synagis Anti-RSV; Humanized IgG1 Prevention of respiratory syncytial virus infection 1999 (1998)
Infliximab Remicade Anti-TNF; Chimeric IgG1 Crohn’s disease 1999 (1998)
Trastuzumab Herceptin Anti-HER2; Humanized IgG1 Breast cancer 2000 (1998)
Gemtuzumab ozogamicin Mylotarg Anti-CD33; Humanized IgG4 Acute myeloid leukemia NA (2000#2010)
Alemtuzumab MabCampath, Campath-1H Anti-CD52; Humanized IgG1 Chronic myeloid leukemia 2001 (2001)
Adalimumab Humira Anti-TNF; Human IgG1 Rheumatoid arthritis 2003 (2002)
Tositumomab + 131I-Tositumomab Bexxar Anti-CD20; Murine IgG2a Non-Hodgkin lymphoma NA (2003)
Efalizumab Raptiva Anti-CD11a; humanized IgG1 Psoriasis 2004 (2003); #2009
Cetuximab Erbitux Anti-EGFR; chimeric IgG1 Colorectal cancer 2004 (2004)
Ibritumomab tiuxetan Zevalin Anti-CD20; murine IgG1 Non-Hodgkin’s lymphoma 2004 (2002)
Omalizumab Xolair Anti-IgE; humanized IgG1 Asthma 2005 (2003)
Bevacizumab Avastin Anti-VEGF; humanized IgG1 Colorectal cancer 2005 (2004)
Natalizumab Tysabri Anti-a4 integrin; humanized IgG4 Multiple sclerosis 2006 (2004)
Ranibizumab Lucentis Anti-VEGF; humanized IgG1 Fab Macular degeneration 2007 (2006)
Panitumumab Vectibix Anti-EGFR; human IgG2 Colorectal cancer 2007 (2006)
Eculizumab Soliris Anti-C5; humanized IgG2/4 Paroxysmal nocturnal hemoglobinuria 2007 (2007)
Certolizumab pegol Cimzia Anti-TNF; humanized Fab, pegylated Crohn disease 2009 (2008)
Golimumab Simponi Anti-TNF; human IgG1 Rheumatoid and psoriatic arthritis, ankylosing spondylitis 2009 (2009)
Canakinumab Ilaris Anti-IL1b; human IgG1 Muckle-Wells syndrome 2009 (2009)
Catumaxomab Removab Anti-EPCAM/CD3;rat/mouse bispecific mAb Malignant ascites 2009 (NA)
Ustekinumab Stelara Anti-IL12/23; human IgG1 Psoriasis 2009 (2009)
Tocilizumab RoActemra, Actemra Anti-IL6R; humanized IgG1 Rheumatoid arthritis 2009 (2010)
Ofatumumab Arzerra Anti-CD20; human IgG1 Chronic lymphocytic leukemia 2010 (2009)
Denosumab Prolia Anti-RANK-L; human IgG2 Bone loss 2010 (2010)
Belimumab Benlysta Anti-BLyS; human IgG1 Systemic lupus erythematosus (2011)
Raxibacumab (Pending) Anti-B. anthrasis PA; human IgG1 Anthrax infection NA (in review)
Ipilimumab Yervoy Anti-CTLA-4; human IgG1 Metastatic melanoma (2011)
Brentuximab vedotin (Pending) Anti-CD30; chimeric IgG1; immunoconjugate Hodgkin lymphoma, systemic ALCL NA (application submitted)

Information current as of July 2011. Updated and modified from Janice M. Reichert, Editor-in-Chief, mAbs

a

Country-specific approval; approved under concertation procedure; #Voluntarily withdrawn from the market. @Supplies are exhausted in 2010. BLyS B lymphocyte stimulator, C5 complement 5, CD cluster of differentiation, CTLA-4 cytotoxic T lymphocyte antigen 4, EGFR epidermal growth factor receptor, EPCAM epithelial cell adhesion molecule, GP glycoprotein, IL interleukin, NA not approved, PA protective antigen, RANK-L receptor activator of NFkb ligand, RSV respiratory syncytial virus, TNF tumor necrosis factor, VEGF vascular endothelial growth factor. Not included here are polyclonal antibodies against infectious diseases and toxins